A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

被引：13

作者：

Patel, Manish R. ^{[1
]}

Monga, Varun ^{[2
]}

Jauhari, Shekeab ^{[1
]}

Stevens, Don ^{[3
]}

Masarova, Lucia ^{[4
]}

McKean, Meredith ^{[5
]}

Mauro, David ^{[6
]}

Viscusi, John ^{[6
]}

Scherle, Peggy ^{[6
]}

Bhagwat, Neha ^{[6
]}

Moore, Andrew ^{[6
]}

Sun, William ^{[6
]}

Chiaverelli, Rachel ^{[6
]}

Mintah, Eric ^{[6
]}

Nath, Rajneesh ^{[7
]}

Stein, Eytan M. ^{[8
]}

Palmisiano, Neil ^{[9
]}

Sutamtewagul, Grerk ^{[2
]}

Verstovsek, Srdan ^{[10
]}

机构：

[1] Florida Canc Specialists & Res Inst, Sarah Cannon Res Inst, Sarasota, FL USA

[2] Univ Iowa Hosp & Clin, Dept Med, Iowa City, IA 52242 USA

[3] NCI, Norton Healthcare, Louisville, KY USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[5] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[6] Prelude Therapeut, Res & Dev, Wilmington, DE USA

[7] Univ Texas MD Anderson Canc Ctr, Banner Hlth, Gilbert, AZ USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[9] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-150938

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2609

引用

页数：7

共 50 条

[31] Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer
Sapir, Tzuriel
Shifteh, David
Pahmer, Moshe
Goel, Sanjay
Maitra, Radhashree
MOLECULAR CANCER RESEARCH, 2021, 19 (03) : 388 - 394
[32] A role for protein arginine methyltransferase 5 (PRMT5) in the mechanism of novel anticancer agent, AS1411.
Teng, Yun
Bates, Paula J.
CANCER RESEARCH, 2006, 66 (08)
[33] The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma
Holmes, Brent
Benavides-Serrato, Angelica
Saunders, Jacquelyn T.
Landon, Kenna A.
Schreck, Adam J.
Nishimura, Robert N.
Gera, Joseph
JOURNAL OF NEURO-ONCOLOGY, 2019, 145 (01) : 11 - 22
[34] The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma
Brent Holmes
Angelica Benavides-Serrato
Jacquelyn T. Saunders
Kenna A. Landon
Adam J. Schreck
Robert N. Nishimura
Joseph Gera
Journal of Neuro-Oncology, 2019, 145 : 11 - 22
[35] Protein arginine methyltransferase 5 (PRMT5) inhibition as a therapeutic strategy in B-cell lymphoma
Barbash, Olena
Gerhart, Sarah
Soong, David
Thompson, Christine
de Oca, Rocio Montes
Zhang, Ping
McHugh, Charles
Kuplast, Kristy
Majer, Christina
Chesworth, Richard
Smith, Jesse
Copeland, Robert
Penebre, Elayne
Duncan, Kenneth
Johnson, Neil
Carpenter, Chris
Kruger, Ryan
CANCER RESEARCH, 2015, 75
[36] PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.
Ahnert, Jordi Rodon
Perez, Cesar Augusto
Wong, Kit Man
Maitland, Michael L.
Tsai, Frank
Berlin, Jordan
Liao, Kai Hsin
Wang, I-Ming
Markovtsova, Lada
Jacobs, Ira A.
Cavazos, Nora
Li, Meng
Tolcher, Anthony W.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[37] Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma
Yan, Fengting
Alinari, Lapo
Lustberg, Mark E.
Martin, Ludmila Katherine
Cordero-Nieves, Hector M.
Banasavadi-Siddegowda, Yeshavanth
Virk, Selene
Barnholtz-Sloan, Jill
Bell, Erica Hlavin
Wojton, Jeffrey
Jacob, Naduparambil K.
Chakravarti, Arnab
Nowicki, Michal O.
Wu, Xin
Lapalombella, Rosa
Datta, Jharna
Yu, Bo
Gordon, Kate
Haseley, Amy
Patton, John T.
Smith, Porsha L.
Ryu, John
Zhang, Xiaoli
Mo, Xiaokui
Marcucci, Guido
Nuovo, Gerard
Kwon, Chang-Hyuk
Byrd, John C.
Chiocca, E. Antonio
Li, Chenglong
Sif, Said
Jacob, Samson
Lawler, Sean
Kaur, Balveen
Baiocchi, Robert A.
CANCER RESEARCH, 2014, 74 (06) : 1752 - 1765
[38] Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor
Rioux, Nathalie
Duncan, Kenneth W.
Lantz, Ronald J.
Miao, Xiusheng
Chan-Penebre, Elayne
Moyer, Mikel P.
Munchhof, Michael J.
Copeland, Robert A.
Chesworth, Richard
Waters, Nigel J.
XENOBIOTICA, 2016, 46 (03) : 268 - 277
[39] Efficacy of the protein arginine methyltransferase PRMT5 inhibitor GSK591 in glioma stem-like cells
Shaw, Vikram
Piao, Yuji
Park, Soon Young
Dong, Jianwen
Martinez-Ledesma, Emmanuel
Carrillo, Caroline
Henry, Verlene
Ezhilarasan, Ravesanker
Sulman, Erik
Balasubramaniyan, Veerakumar
de Groot, John F.
CANCER RESEARCH, 2018, 78 (13)
[40] The histone-binding protein COPR5 is required for nuclear functions of the protein arginine methyltransferase PRMT5
Lacroix, Matthieu
El Messaoudi, Selma
Rodier, Genevieve
Le Cam, Aphonse
Sardet, Claude
Fabbrizio, Eric
EMBO REPORTS, 2008, 9 (05) : 452 - 458

← 1 2 3 4 5 →